NEW YORK (GenomeWeb) – Monsanto announced two new licensing agreements for genome editing technologies with Israel's TargetGene Biotechnologies and Germany's Nomad Bioscience.

Under the terms of the TargetGene agreement, Monsanto has obtained an exclusive license to the firm's genome editing engine (T-Gee) and an equity position in the privately owned firm. T-Gee is based on RNA-directed gene targeting, the firms said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.